Trials / Unknown
UnknownNCT02100462
Chlorthalidone and HCTZ Impacts on Platelet Activation
Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Creighton University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chlorthalidone 12.5 mg | |
| DRUG | Hydrochlorothiazide 25 mg | |
| DRUG | Aspirin 81 mg |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-04-01
- Last updated
- 2015-12-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02100462. Inclusion in this directory is not an endorsement.